Activated astrocytes: A therapeutic target in Alzheimer's disease?

Expert Review of Neurotherapeutics

Volumn 9, Issue 11, 2009, Pages 1585-1594

  Fuller, Stacey ^a   Münch, Gerald ^a   Steele, Megan ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Glucose; Glutamate; Glutathione; Lactate; Neurodegeneration

Indexed keywords

GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; LACTIC ACID;

ALZHEIMER DISEASE; ASTROCYTE; CELL ACTIVATION; CELL INTERACTION; DISEASE COURSE; DRUG TARGETING; ENERGY METABOLISM; GLUCOSE TRANSPORT; GLUTATHIONE METABOLISM; HUMAN; INFLAMMATION; MACROGLIA; MICROGLIA; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SYNAPSE;

ALZHEIMER DISEASE; ANIMALS; ASTROCYTES; HUMANS;

EID: 70849102524     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.111     Document Type: Review

References (104)

1. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 16(3), 271-278 (1995).
2. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid β-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol. Aging 23(5), 655-664 (2002).
3. Smith M, Richey Harris P, Sayre L, Beckman J, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17(8), 2653-2657 (1997).
4. Halliday G, Robinson S, Shepherd C, Kril J. Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin. Exp. Pharmacol. Physiol. 27(1-2), 1-8 (2000).
5. Griffin WS, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54(2), 276-281 (1995).
6. Meda L, Cassatella MA, Szendrei GI et al. Activation of microglial cells by β-amyloid protein and interferon-α. Nature 374(6523), 647-650 (1995).
7. Pachter JS. Inflammatory mechanisms in Alzheimer disease: the role of β-amyloid/glial interactions. Mol. Psychiatry 2(2), 91-95 (1997).
8. Wang D, Bordey A. The astrocyte odyssey. Prog. Neurobiol. 86(4), 342-367 (2008).
9. Gavillet M, Allaman I, Magistretti PJ. Modulation of astrocytic metabolic phenotype by proinflammatory cytokines. Glia 56(9), 975-989 (2008).
10. Frederickson R. Astroglia in Alzheimer's disease. Neurobiol. Aging 13(2), 239-253 (1992).
11. Bouzier-Sore AK, Serres S, Canioni P, Merle M. Lactate involvement in neuron-glia metabolic interaction: 13C-NMR spectroscopy contribution. Biochimie 85(9), 841-848 (2003).
12. Benarroch E. Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. Mayo Clin. Proc. 80, 1326-1338 (2005).
13. Oz G, Seaquist ER, Kumar A et al. Human brain glycogen content and metabolism: implications on its role in brain energy metabolism. Am. J. Physiol. Endocrinal. Metab. 292(3), 946-951 (2006).
14. Pellerin L, Magistretti P. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc. Natl Acad. Sci. USA 91(22), 10625-10629 (1994).
15. Bittar PG, Charnay Y, Pellerin L, Bouras C, Magistretti PJ. Selective distribution of lactate dehydrogenase isoenzymes in neurons and astrocytes of human brain. J. Cereb. Blood Flow Metab. 16(6), 1079-1089 (1996).
16. Sokoloff L. Measurement of local cerebral glucose utilization and its relation to local functional activity in the brain. Adv. Exp. Med. Biol. 291, 21-42 (1991).
17. Pascual JM, van Heertum RL, Wang D, Engelstald K, De Vivo DC. Imaging the metabolic footprint of Glut1 deficiency on the brain. Ann. Neurol. 52(4), 458-464 (2002).
18. Aubert A, Costalat R. Interaction between astrocytes and neurons studied using a mathematical model of compartmentalized energy metabolism. J. Cereb. Blood Flow Metabol. 25(11), 1476-1490 (2005).
19. Magistretti PJ. Cellular bases of functional brain imaging: insights from neuron-glia metabolic coupling. Brain Res. 886(1-2), 108-112 (2000).
20. Magistretti P, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Phil. Trans. Biol. Sci. 354, 1155-1163 (1999).
21. Magistretti P, Pellerin L, Rothman D, Shulman R. Energy on demand. Science 283(5401), 496-497 (1999).
22. Aubert A, Costalat R, Magistretti PJ, Pellerin L. Brain lactate kinetics: modeling evidence for neuronal lactate uptake upon activation. Proc. Natl Acad. Sci. USA 102(45), 16448-16453 (2005).
23. +-mediated metabolic waves. Proc. Natl Acad. Sci. USA 101(41), 14937-14942 (2004).
24. Hertz L, Dringen R, Schousboe A, Robinson SR. Astrocytes: glutamate producers for neurons. J. Neurosci. Res. 57(4), 417-428 (1999).
25. Anderson C, Swanson R. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 32(1), 1-14 (2000).
26. Pellerin L, Pellegri G, Bittar P et al. Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev. Neurosci. 20, 291-299 (1998).
27. Kirchhoff F, Dringen R, Giaume C. Pathways of neuron-astrocyte interactions and their possible role in neuroprotection. Eur. Arch. Psychiatry Clin. Neurosci. 251(4), 159-169 (2001).
28. Aschner M. Neuron-astrocyte interactions: implications for cellulalr energetics and antioxidant levels. Neurotoxicology 21(6), 1101-1107 (2000).
29. Sagara JI, Miura K, Bannai S. Maintenance of neuronal glutathione by glial cells. J. Neurochem. 61(5), 1672-1676 (1993).
30. Dringen R, Gutterer JM, Gros C, Hirrlinger J. Aminopeptidase N mediates the utilization of the GSH precursor CysGly by cultured neurons. J. Neurosci. Res. 66(5), 1003-1008 (2001).
31. Dringen R. Metabolism and functions of glutathione in brain. Prog. Neurobiol. 62(6), 649-671 (2000).
32. Deuther-Conrad W, Loske C, Schinzel R, Dringen R, Riederer P, Münch G. Advanced glycation endproducts change glutathione redox status in SH-SY5Y human neuroblastoma cells by a hydrogen peroxide dependent mechanism. Neurosci. Lett. 312(1), 29-32 (2001).
33. Reilly JF, Maher PA, Kumari VG. Regulation of astrocyte GFAP expression by TGF-β1 and FGF-2. Glia 22(2), 202-210 (1998).
34. Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 20(12), 570-577 (1997).
35. Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21(3), 383-421 (2000).
36. Simpson J, Ince P, Lace G et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol. Aging DOI: 10.1016/j. neurobiolaging.2008.05.015 (2008) (Epub ahead of print).
37. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J. Neurosci. 18(20), 8126-8132 (1998).
38. Paris D, Townsend KP, Obregon DF, Humphrey J, Mullan M. Pro-inflammatory effect of freshly solubilized β-amyloid peptides in the brain. Prostaglandins Other Lipid Mediat. 70(1-2), 1-12 (2002).
39. + astrocytes with neurofibrillary tangle stages. J. Neuropathol. Exp. Neurol. 56(3), 285-290 (1997).
40. Ikeda K, Haga C, Akiyama H, Kase K, Iritani S. Coexistence of paired helical filaments and glial filaments in astrocytic processes within ghost tangles. Neurosci. Lett. 148(1-2), 126-128 (1992).
41. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 17(4), 359-365 (2005).
42. Bsibsi M, Persoon-Deen C, Verwer RW, Meeuwsen S, Ravid R, Van Noort JM. Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia 53(7), 688-695 (2006).
43. Bowman CC, Rasley A, Tranguch SL, Marriott I. Cultured astrocytes express Toll-like receptors for bacterial products. Glia 43(3), 281-291 (2003).
44. Wanner IB, Deik A, Torres M et al. A new in vitro model of the glial scar inhibits axon growth. Glia 56(15), 1691-1709 (2008).
45. Pulver M, Carrel S, Mach JP, de Tribolet N. Cultured human fetal astrocytes can be induced by interferon-γ to express HLA-DR. J. Neuroimmunol. 14(2), 123-133 (1987).
46. Skias DD, Kim DK, Reder AT, Antel JP, Lancki DW, Fitch FW. Susceptibility of astrocytes to class I MHC antigen-specific cytotoxicity. J. Immunol. 138(10), 3254-3258 (1987).
47. Hickey WF, Osborn JP, Kirby WM. Expression of Ia molecules by astrocytes during acute experimental allergic encephalomyelitis in the Lewis rat. Cell. Immunol. 91(2), 528-535 (1985).
48. Male DK, Pryce G, Hughes CC. Antigen presentation in brain: MHC induction on brain endothelium and astrocytes compared. Immunology 60(3), 453-459 (1987).
49. Grenier Y, Ruijs TC, Robitaille Y, Olivier A, Antel JP. Immunohistochemical studies of adult human glial cells. J. Neuroimmunol. 21(2-3), 103-115 (1989).
50. Dong Y, Benveniste EN. Immune function of astrocytes. Glia 36(2), 180-190 (2001).
51. Benveniste E. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev. 9(3-4), 259-275 (1998).
52. Tuppo E, Arias H. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 37(2), 289-305 (2005).
53. Dong Y, Benveniste E. Immune function of astrocytes. Glia 36(2), 180-190 (2001).
54. Pasternack J, Abraham C, Van Dyke B, Potter H, Younkin S. Astrocytes in Alzheimer's disease gray matter express a 1-antichymotrypsin mRNA. Am. J. Pathol. 135(5), 827-834 (1989).
55. Beach T, McGeer E. Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer's disease visual cortex. Brain Res. 463(2), 357-361 (1988).
56. Marshak DR, Pesce SA, Stanley LC, Griffin W. Increased S100 b neurotrophic activity in Alzheimer's disease temporal lobe. Neurobiol. Aging 13(1), 1-7 (1992).
57. Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer's disease: a progression factor for amyloid-β-induced cellular perturbation? J. Alzheimers Dis. 16(4), 833-843 (2009).
58. Wang Z, Li DD, Liang YY, Wang DS, Cai NS. Activation of astrocytes by advanced glycation end products: cytokines induction and nitric oxide release. Acta Pharmacol. Sin. 23(11), 974-980 (2002).
59. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 3(4), 169-176 (2004).
60. Mrak RE, Sheng JG, Griffin WS. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum. Pathol. 26(8), 816-823 (1995).
61. Retz W, Gsell W, Münch G, Rosler M, Riederer P. Free radicals in Alzheimer's disease. J. Neural Transm. Suppl. 54, 221-236 (1998).
62. McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Ann. NY Acad. Sci. 1035, 104-116 (2004).
63. Simonian N, Coyle J. Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 36(1), 83-106 (1996).
64. Behl C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog. Neurobiol. 57(3), 301-323 (1999).
65. Christen Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71(2), S621-S629 (2000).
66. Aksenov M, Aksenova M, Butterfield DA, Markesbery WR. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J. Neurochem. 74(6), 2520-2527 (2000).
67. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103(2), 373-383 (2001).
68. Castegna A, Aksenov M, Aksenova M et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33(4), 562-571 (2002).
69. Castegna A, Aksenov M, Thongboonkerd V et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, α-enolase and heat shock cognate 71. J. Neurochem. 82(6), 1524-1532 (2002).
70. Castegna A, Thongboonkerd V, Klein J, Lynn B, Markesbery W, Butterfield D. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85(6), 1394 (2003).
71. Gow A, Duran D, Malcolm S, Ischiropoulos H. Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation. FEBS Lett. 385(1-2), 63-66 (1996).
72. Sultana R, Poon H, Cai J et al. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 22(1), 76-87 (2006).
73. Butterfield D, Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev. 122(9), 945-962 (2001).
74. Butterfield D, Stadtman E. Protein oxidation processes in aging brain. Adv. Cell Aging Gerontol. 2, 161-191 (1997).
75. Lüth HJ, Münch G, Arendt T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res. 953(1-2), 135-143 (2002).
76. Fernandez-Vizarra P, Fernandez A, Castro-Blanco S et al. Expression of nitric oxide system in clinically evaluated cases of Alzheimer's disease. Neurobiol. Dis. 15(2), 287-305 (2004).
77. Pacher P, Beckman J, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87(1), 315 (2007).
78. Good P, Werner P, Hsu A, Olanow C, Perl D. Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149(1), 21-28 (1996).
79. Vodovotz Y, Lucia M, Flanders K et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med. 184(4), 1425-1433 (1996).
80. Freemantle E, Vandal M, Tremblay-Mercier J et al. Omega-3 fatty acids, energy substrates, and brain function during aging. Prostaglandins Leukot. Essent. Fatty Acids 75(3), 213-220 (2006).
81. Alexander G, Chen K, Pietrini P, Rapopor S, Reiman E. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J Psychiatry 159(5), 738-745 (2002).
82. Small GW, Ercoli LM, Silverman DH et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA 97(11), 6037-6042 (2000).
83. Li S, Mallory M, Alford M, Tanaka S, Masliah E. Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J. Neuropathol. Exp. Neurol. 56(8), 901-911 (1997).
84. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann. Neurol. 40(5), 759-766 (1996).
85. Scott H, Pow D, Tannenberg A, Dodd P. Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease. J. Neurosci. 22(3), RC206 (2002).
86. Smith GM, Miller RH. Immature type-1 astrocytes suppress glial scar formation, are motile and interact with blood vessels. Brain Res. 543(1), 111-122 (1991).
87. Butterfield DA, Hensley K, Cole P et al. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J. Neurochem. 68(6), 2451-2457 (1997).
88. Calabrese V, Sultana R, Scapagnini G et al. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid. Redox Signal. 8, 1975-1986 (2006).
89. Reed T, Perluigi M, Sultana R et al. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis. 30(1), 107-120 (2008).
90. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32(11), 1050-1060 (2002).
91. Butterfield DA, Sultana R. Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J. Alzheimers Dis. 12(1), 61-72 (2007).
92. Karelson E, Bogdanovic N, Garlind A et al. The cerebrocortical areas in normal brain aging and in Alzheimer's disease: noticeable differences in the lipid peroxidation level and in antioxidant defense. Neurochem. Res. 26(4), 353-361 (2001).
93. Butterfield DA, Boyd-Kimball D. Proteomics analysis in Alzheimer's disease: new insights into mechanisms of neurodegeneration. Int. Rev. Neurobiol. 61, 159-188 (2004).
94. Newman S, Sultana R, Perluigi M et al. An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J. Neurosci. Res. 85(7), 1506-1514 (2007).
95. Giustarini D, Rossi R, Milzani A, Colombo R, Dalle-Donne I. S-glutathionylation: from redox regulation of protein functions to human diseases. J. Cell. Mol. Med. 8(2), 201-212 (2004).
96. Dalle-Donne I, Milzani A, Gagliano N, Colombo R, Giustarini D, Rossi R. Molecular mechanisms and potential clinical significance of S-glutathionylation. Antioxid. Redox Signal. 10(3), 445-473 (2008).
97. Hensley K, Robinson K, Gabbita S, Salsman S, Floyd R. Reactive oxygen species, cell signaling, and cell injury. Free Radic. Biol. Med. 28(10), 1456-1462 (2000).
98. Babior B. NADPH oxidase: an update. Blood, 93(5), 1464-1476 (1999).
99. Holland J, O'Donnell R, Chang M, Johnson D, Ziegler L. Endothelial cell oxidant production: effect of NADPH oxidase inhibitors. Endothelium 7(2), 109-119 (2000).
100. Pahan K, Sheikh F, Namboodiri A, Singh I. Inhibitors of protein phosphatase 1 and 2A differentially regulate the expression of inducible nitric-oxide synthase in rat astrocytes and macrophages. J. Biol. Chem. 273(20), 12219-12226 (1998).
101. Issels RD, Nagele A, Eckert KG, Wilmanns W. Promotion of cystine uptake and its utilization for glutathione biosynthesis induced by cysteamine and N-acetylcysteine. Biochem. Pharmacol. 37(5), 881-888 (1988).
102. Issels RD, Nagele A. Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino) ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells. Cancer Res. 49(8), 2082-2086 (1989).
103. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology 57(8), 1515-1517 (2001).
104. Begni B, Brighina L, Sirtori E et al. Oxidative stress impairs glutamate uptake in fibroblasts from patients with Alzheimer's disease. Free Radic. Biol. Med. 37(6), 892-901 (2004).